

**National Center for Emerging and Zoonotic
Infectious Diseases**



Characterization of Invasive Salmonellosis in Hospitalized Children with Acute Febrile Illness— Uganda, 2016–2017

Alison Winstead, MD
Epidemic Intelligence Service Officer
Waterborne Disease Prevention Branch

11th International Conference on Typhoid and Other Invasive Salmonellosis
March 26–28, 2019

**Uganda Acute Febrile
Illness (AFI) Project**



Objectives

- **Establish leading causes of non-malarial acute febrile illness among hospitalized children in Uganda**



Objectives

- **Establish leading causes of non-malarial acute febrile illness among hospitalized children in Uganda**
- **Provide guidance for further expansion of relevant diagnostic capacity**






Objectives

- **Establish leading causes of non-malarial acute febrile illness among hospitalized children in Uganda**
- **Provide guidance for further expansion of relevant diagnostic capacity**
- **Obtain antimicrobial resistance patterns to guide proper use of antimicrobial therapies**



Uganda AFI surveillance sites





Further serologic testing: arboviruses, *Rickettsia*, *Borrelia*, *Brucella




**Uganda AFI project
(July 1, 2016 – Nov 16, 2017)**


22,553
hospitalized children
(≤ 14 years)



**Uganda AFI project
(July 1, 2016 – Nov 16, 2017)**




Uganda AFI project
(July 1, 2016 – Nov 16, 2017)




Pathogens identified by blood culture Uganda AFI Project: Jul 2016 – Nov 2017

n=143



Pathogens identified by blood culture Uganda AFI Project: Jul 2016 – Nov 2017

n=143




Descriptive characteristics
Uganda AFI project: Jul 2016 – Nov 2017


	Children with <i>Salmonella</i> bacteremia (n=57)	Children without <i>Salmonella</i> bacteremia (n=22,496)	P value
Median age (range)	3 years (0–12)	2 years (0–14)	0.026
Male (%)	40 (70%)	12,627 (57%)	0.04
Death (%)	3 (6%)	843 (4%)	0.537




Median length of hospital stay Uganda AFI Project: Jul 2016 – Nov 2017




Salmonella serotypes
Uganda AFI Project: Jul 2016 – Nov 2017
n=49



Percentage of nontyphoidal and typhoidal serotypes
Uganda AFI Project: Jul 2016 – Nov 2017
n=49




Uganda AFI surveillance sites



Percentage of *Salmonella* bacteremia
per number of blood cultures drawn, by site
Uganda AFI Project: Jul 2016 – Nov 2017


n=57



Salmonella serotypes by site

Uganda AFI Project: Jul 2016 – Nov 2017

n=47




**Antimicrobial
Resistance**



Antimicrobial resistance of *Salmonella* isolates Uganda AFI Project: Jul 2016 – Nov 2017

n=49




*trimethoprim-sulfamethoxazole (TMP-SMX)




Antimicrobial resistance patterns by serotype Uganda AFI Project: Jul 2016 – Nov 2017

n=49



**Antimicrobial resistance patterns,
grouped as nontyphoidal or typhoidal
Uganda AFI Project: Jul 2016 – Nov 2017
n=49**



Discussion



Limitations

- **Blood culture collection proportions**



Limitations

- **Blood culture collection proportions**
 - Staffing
 - Stockouts
 - Clinician discretion



Limitations

- **Blood culture collection proportions**
 - Staffing
 - Stockouts
 - Clinician discretion
- **Laboratory challenges**



Conclusions

- ***Salmonella* is the most commonly detected cause of bacteremia in febrile hospitalized children in Uganda**



Conclusions

- ***Salmonella* is the most commonly detected cause of bacteremia in febrile hospitalized children in Uganda**
- **71% of *Salmonella* serotypes causing bacteremia were identified as nontyphoidal**



Conclusions

- ***Salmonella* is the most commonly detected cause of bacteremia in febrile hospitalized children in Uganda**
- **71% of *Salmonella* serotypes causing bacteremia were identified as nontyphoidal**
- **Antimicrobial resistance continues to threaten our ability to properly treat invasive *Salmonella* infections**



Acknowledgments

Centers for Disease Control and Prevention

DFWED

Grace Appiah
Eric Mintz
Molly Freeman
Kirsten Fagerli
Rupa Narra

DVBD

Kiersten Kugeler
Paul Mead
Jeff Borchert

DGHP

George Odongo
Ray Ransom
Matt Mikoleit

CDC Uganda

Lisa Nelson
Vance Brown
Jaco Homsy

Infectious Disease Research Collaboration

Arthur Mpimbaza
Asadu Sserwanga
James Kapisi
Catherine Maiteki
Moses Kamywa
Abel Kusemererwa
Jane Frances Namuganga

Infectious Diseases Institute

Mohammed Lamorde
Richard Walwema
Franklin Kizito
Yukari Manabe

Makerere University Microbiology Laboratory

Henry Kajumbula
Hannington Tasimwa

Uganda Virus Research Institute

Robert Downing
Apac District Hospital
Arua Regional Referral Hospital
Jinja Regional Referral Hospital
Kabale Regional Referral Hospital
Mubende Regional Referral Hospital
Tororo District Hospital



The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.





Extra Slides

Risk factors previously associated with iNTS

- HIV infection
- Malnutrition
- Malaria
- Young age
- Anemia
- Rural setting




Contaminants

- **CONS**
- **Corynebacterium**
- **Bacillus**
- **Micrococcus**
- **Strep viridans**
- **"bloodcultureresult" = 2 "contaminant" with no organism identified**




Number of children with *Salmonella* bacteremia by site
(Uganda AFI project: Jul 2016 – Nov 2017)

n=57



Number of blood cultures done by site




Malaria

**Proportion of *Salmonella* bacteremia patients
positive for malaria**

Uganda AFI Project: Jul 2016 – Nov 2017


n=54



■ malaria positive ■ malaria negative




Proportion of tested patients positive for malaria, by site
Uganda AFI Project: Jul 2016 – Nov 2017
n=19,882



Diagnoses/Antibiotics


**Most common admission diagnoses of all children
Uganda AFI Project: Jul 2016 – Nov 2017
n=20,762***




Most common antibacterial medications given to all hospitalized children

Uganda AFI Project: Jul 2016 – Nov 2017

n=21,544



**Admission diagnoses in children
with *Salmonella* bacteremia
Uganda AFI Project: Jul 2016 – Nov 2017
n=51***



*12% missing data


Antibiotic



Antibacterial medications received by children with *Salmonella* bacteremia

Uganda AFI Project: Jul 2016 – Nov 2017

n=55



Salmonella deaths

Description of deaths with *Salmonella* bacteremia

Age in years	Sex	Location	Length of stay in days	Lab test positive for malaria	Diagnoses	Medications given
7	Male	Arua	16	Yes	Severe malaria Sickle cell disease Anemia Respiratory infection	artesunate IV penicillin IV amoxicillin oral
1	Male	Arua	6	Yes	Severe malaria Septicaemia	artesunate IV
3	Male	Jinja	1	No	Pneumonia	artesunate IV gentamicin ampicillin




**Antimicrobial susceptibility patterns of children
who died with *Salmonella* bacteremia**

	<u>ampicillin</u>	<u>cotrimoxazole</u>	<u>ciprofloxacin</u>	<u>ceftriaxone</u>
Child 1	resistant	resistant	susceptible	resistant
Child 2	susceptible		susceptible	
Child 3	susceptible	resistant	susceptible	intermediate




Seasonality

Salmonella cases by month



Children included in Uganda AFI project in Arua, by month (average)



Number of children diagnosed with *Salmonella* bacteremia in Arua, by month (average)

